(RMD) ResMed - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US7611521078
Sleep Apnea Devices, Ventilators, Cloud Software
Dividends
| Dividend Yield | 0.88% |
| Yield on Cost 5y | 1.13% |
| Yield CAGR 5y | 6.67% |
| Payout Consistency | 100.0% |
| Payout Ratio | 22.8% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 37.2% |
| Value at Risk 5%th | 50.7% |
| Relative Tail Risk | -17.07% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.17 |
| Alpha | -6.26 |
| CAGR/Max DD | 0.14 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.510 |
| Beta | 0.642 |
| Beta Downside | 0.559 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.87% |
| Mean DD | 12.96% |
| Median DD | 9.16% |
Description: RMD ResMed December 03, 2025
ResMed Inc. (NYSE:RMD) designs, manufactures and sells medical devices and cloud-based software for diagnosing, treating and managing respiratory disorders, chiefly sleep apnea. Its operations fall into two segments: Sleep and Breathing Health, and Residential Care Software. Core product lines include portable diagnostic devices such as ApneaLink Air and NightOwl, the AirView remote-monitoring platform, the patient-focused myAir app, and a suite of software solutions (Brightree, HEALTHCAREfirst, MatrixCare, MEDIFOX DAN) serving home-health, hospice, skilled-nursing and senior-living providers.
Key quantitative signals (FY 2023): revenue $3.6 billion, up ~9 % YoY; operating margin ~22 %; and a 12 % growth in the AirView subscription base, reflecting rising demand for tele-monitoring. The sleep-apnea market is expanding at ~6 % CAGR, driven by an aging population, higher obesity rates, and broader insurance reimbursement for home-based diagnostics. A material sector catalyst is the ongoing shift toward value-based care, which rewards devices that improve compliance and reduce hospital readmissions.
For a deeper quantitative breakdown, you may want to explore the RMD profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (1.44b TTM) > 0 and > 6% of Revenue (6% = 315.4m TTM) |
| FCFTA 0.21 (>2.0%) and ΔFCFTA 2.62pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 45.08% (prev 36.13%; Δ 8.95pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.23 (>3.0%) and CFO 1.88b > Net Income 1.44b (YES >=105%, WARN >=100%) |
| Net Debt (-537.5m) to EBITDA (1.98b) ratio: -0.27 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.89 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (147.0m) change vs 12m ago -0.38% (target <= -2.0% for YES) |
| Gross Margin 60.08% (prev 57.20%; Δ 2.88pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 67.70% (prev 66.56%; Δ 1.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 87.15 (EBITDA TTM 1.98b / Interest Expense TTM 20.1m) >= 6 (WARN >= 3) |
Altman Z'' 8.89
| (A) 0.29 = (Total Current Assets 3.63b - Total Current Liabilities 1.26b) / Total Assets 8.31b |
| (B) 0.76 = Retained Earnings (Balance) 6.34b / Total Assets 8.31b |
| (C) 0.23 = EBIT TTM 1.75b / Avg Total Assets 7.77b |
| (D) 2.87 = Book Value of Equity 6.28b / Total Liabilities 2.19b |
| Total Rating: 8.89 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 94.61
| 1. Piotroski 8.0pt |
| 2. FCF Yield 4.95% |
| 3. FCF Margin 33.61% |
| 4. Debt/Equity 0.14 |
| 5. Debt/Ebitda -0.27 |
| 6. ROIC - WACC (= 13.20)% |
| 7. RoE 25.13% |
| 8. Rev. Trend 96.85% |
| 9. EPS Trend 95.70% |
What is the price of RMD shares?
As of December 07, 2025, the stock is trading at USD 256.55 with a total of 578,001 shares traded.
Over the past week, the price has changed by +0.28%, over one month by +4.87%, over three months by -7.18% and over the past year by +8.11%.
Over the past week, the price has changed by +0.28%, over one month by +4.87%, over three months by -7.18% and over the past year by +8.11%.
Is RMD a buy, sell or hold?
ResMed has received a consensus analysts rating of 3.95.
Therefore, it is recommended to buy RMD.
- Strong Buy: 8
- Buy: 4
- Hold: 6
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the RMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 293.5 | 14.4% |
| Analysts Target Price | 293.5 | 14.4% |
| ValueRay Target Price | 250.2 | -2.5% |
RMD Fundamental Data Overview December 03, 2025
Market Cap USD = 36.26b (36.26b USD * 1.0 USD.USD)
P/E Trailing = 25.4488
P/E Forward = 23.4742
P/S = 6.896
P/B = 6.1005
P/EG = 1.6478
Beta = 0.87
Revenue TTM = 5.26b USD
EBIT TTM = 1.75b USD
EBITDA TTM = 1.98b USD
Long Term Debt = 408.7m USD (from longTermDebt, last quarter)
Short Term Debt = 289.9m USD (from shortTermDebt, last quarter)
Debt = 846.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -537.5m USD (from netDebt column, last quarter)
Enterprise Value = 35.72b USD (36.26b + Debt 846.4m - CCE 1.38b)
Interest Coverage Ratio = 87.15 (Ebit TTM 1.75b / Interest Expense TTM 20.1m)
FCF Yield = 4.95% (FCF TTM 1.77b / Enterprise Value 35.72b)
FCF Margin = 33.61% (FCF TTM 1.77b / Revenue TTM 5.26b)
Net Margin = 27.35% (Net Income TTM 1.44b / Revenue TTM 5.26b)
Gross Margin = 60.08% ((Revenue TTM 5.26b - Cost of Revenue TTM 2.10b) / Revenue TTM)
Gross Margin QoQ = 61.46% (prev 60.84%)
Tobins Q-Ratio = 4.30 (Enterprise Value 35.72b / Total Assets 8.31b)
Interest Expense / Debt = 1.04% (Interest Expense 8.79m / Debt 846.4m)
Taxrate = 21.99% (98.3m / 446.8m)
NOPAT = 1.37b (EBIT 1.75b * (1 - 21.99%))
Current Ratio = 2.89 (Total Current Assets 3.63b / Total Current Liabilities 1.26b)
Debt / Equity = 0.14 (Debt 846.4m / totalStockholderEquity, last quarter 6.12b)
Debt / EBITDA = -0.27 (Net Debt -537.5m / EBITDA 1.98b)
Debt / FCF = -0.30 (Net Debt -537.5m / FCF TTM 1.77b)
Total Stockholder Equity = 5.72b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.31% (Net Income 1.44b / Total Assets 8.31b)
RoE = 25.13% (Net Income TTM 1.44b / Total Stockholder Equity 5.72b)
RoCE = 28.62% (EBIT 1.75b / Capital Employed (Equity 5.72b + L.T.Debt 408.7m))
RoIC = 21.41% (NOPAT 1.37b / Invested Capital 6.39b)
WACC = 8.21% (E(36.26b)/V(37.10b) * Re(8.38%) + D(846.4m)/V(37.10b) * Rd(1.04%) * (1-Tc(0.22)))
Discount Rate = 8.38% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.17%
[DCF Debug] Terminal Value 80.36% ; FCFE base≈1.60b ; Y1≈1.97b ; Y5≈3.37b
Fair Price DCF = 367.4 (DCF Value 53.62b / Shares Outstanding 146.0m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 95.70 | EPS CAGR: 15.82% | SUE: 0.52 | # QB: 0
Revenue Correlation: 96.85 | Revenue CAGR: 11.27% | SUE: 0.20 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.77 | Chg30d=+0.022 | Revisions Net=+6 | Analysts=13
EPS current Year (2026-06-30): EPS=10.90 | Chg30d=+0.052 | Revisions Net=+12 | Growth EPS=+14.2% | Growth Revenue=+8.9%
EPS next Year (2027-06-30): EPS=12.02 | Chg30d=+0.064 | Revisions Net=+6 | Growth EPS=+10.2% | Growth Revenue=+7.4%
P/E Trailing = 25.4488
P/E Forward = 23.4742
P/S = 6.896
P/B = 6.1005
P/EG = 1.6478
Beta = 0.87
Revenue TTM = 5.26b USD
EBIT TTM = 1.75b USD
EBITDA TTM = 1.98b USD
Long Term Debt = 408.7m USD (from longTermDebt, last quarter)
Short Term Debt = 289.9m USD (from shortTermDebt, last quarter)
Debt = 846.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -537.5m USD (from netDebt column, last quarter)
Enterprise Value = 35.72b USD (36.26b + Debt 846.4m - CCE 1.38b)
Interest Coverage Ratio = 87.15 (Ebit TTM 1.75b / Interest Expense TTM 20.1m)
FCF Yield = 4.95% (FCF TTM 1.77b / Enterprise Value 35.72b)
FCF Margin = 33.61% (FCF TTM 1.77b / Revenue TTM 5.26b)
Net Margin = 27.35% (Net Income TTM 1.44b / Revenue TTM 5.26b)
Gross Margin = 60.08% ((Revenue TTM 5.26b - Cost of Revenue TTM 2.10b) / Revenue TTM)
Gross Margin QoQ = 61.46% (prev 60.84%)
Tobins Q-Ratio = 4.30 (Enterprise Value 35.72b / Total Assets 8.31b)
Interest Expense / Debt = 1.04% (Interest Expense 8.79m / Debt 846.4m)
Taxrate = 21.99% (98.3m / 446.8m)
NOPAT = 1.37b (EBIT 1.75b * (1 - 21.99%))
Current Ratio = 2.89 (Total Current Assets 3.63b / Total Current Liabilities 1.26b)
Debt / Equity = 0.14 (Debt 846.4m / totalStockholderEquity, last quarter 6.12b)
Debt / EBITDA = -0.27 (Net Debt -537.5m / EBITDA 1.98b)
Debt / FCF = -0.30 (Net Debt -537.5m / FCF TTM 1.77b)
Total Stockholder Equity = 5.72b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.31% (Net Income 1.44b / Total Assets 8.31b)
RoE = 25.13% (Net Income TTM 1.44b / Total Stockholder Equity 5.72b)
RoCE = 28.62% (EBIT 1.75b / Capital Employed (Equity 5.72b + L.T.Debt 408.7m))
RoIC = 21.41% (NOPAT 1.37b / Invested Capital 6.39b)
WACC = 8.21% (E(36.26b)/V(37.10b) * Re(8.38%) + D(846.4m)/V(37.10b) * Rd(1.04%) * (1-Tc(0.22)))
Discount Rate = 8.38% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.17%
[DCF Debug] Terminal Value 80.36% ; FCFE base≈1.60b ; Y1≈1.97b ; Y5≈3.37b
Fair Price DCF = 367.4 (DCF Value 53.62b / Shares Outstanding 146.0m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 95.70 | EPS CAGR: 15.82% | SUE: 0.52 | # QB: 0
Revenue Correlation: 96.85 | Revenue CAGR: 11.27% | SUE: 0.20 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.77 | Chg30d=+0.022 | Revisions Net=+6 | Analysts=13
EPS current Year (2026-06-30): EPS=10.90 | Chg30d=+0.052 | Revisions Net=+12 | Growth EPS=+14.2% | Growth Revenue=+8.9%
EPS next Year (2027-06-30): EPS=12.02 | Chg30d=+0.064 | Revisions Net=+6 | Growth EPS=+10.2% | Growth Revenue=+7.4%
Additional Sources for RMD Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle